Shares of Avalo Therapeutics (NASDAQ:AVTX) climbed on Friday as Wedbush launched its coverage with an Outperform recommendation and an $18 per share target, citing the potential of the biotech’s lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback